A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing antifactor Xa/antifactor IIa ratio in the rabbit
- 1 April 1993
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 83 (4), 622-626
- https://doi.org/10.1111/j.1365-2141.1993.tb04700.x
Abstract
This study compares the ability of unfractionated heparin (UH) and of three low molecular weight heparins (LMWHs) to inhibit venous thrombosis growth in the rabbit. Logiparin (LHN-1), Fraxiparin (CY216) and CY222 were selected because they present very different antifactor Xa/antifactor IIa ratios: 1.7, 3.8 and 6.8 respectively. Heparins were delivered under continuous intravenous infusion for 4 h at increasing doses from 10 to 250 antifactor Xa U kg-1 h-1. The minimum dose providing the maximum inhibitory effect was 50 antifactor Xa U kg-1 h-1. On the basis of this system of units the four heparins were equipotent antithrombotic agents. Due to the highest antifactor Xa/antifactor IIa ratio, CY222 became the most potent antithrombotic agent when the doses were expressed in antithrombin units. Because UH is cleared faster than LMWHs at low dose regimen, the antifactor Xa steady state concentrations generated by the continuous infusion of any of the LMWHs were higher than those generated by UH. In addition the ex vivo antifactor Xa/antifactor IIa ratio of each of the LMWH was superior to the in vitro ratio. These results indicate that the antithrombotic activity of LMWH is not directly related to its subfraction catalysing thrombin inhibition.Keywords
This publication has 16 references indexed in Scilit:
- Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein ThrombosisNew England Journal of Medicine, 1992
- On the Relationship Between Molecular Mass and Anticoagulant Activity in a Low Molecular Weight Heparin (Enoxaparin)Thrombosis and Haemostasis, 1992
- Pharmacokinetics of Heparin and of Dermatan Sulfate: Clinical ImplicationsPublished by Springer Nature ,1992
- Antithrombotic potencies of heparins in relation to their antifactor Xa and antithrombin activities: an experimental study in two models of thrombosis in the rabbitBritish Journal of Haematology, 1990
- Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.Circulation, 1989
- Biochemical and Pharmacologic Inequivalence of Low Molecular Weight HeparinsAnnals of the New York Academy of Sciences, 1989
- Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growthThrombosis Research, 1985
- Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4Biochemical Journal, 1984
- Fractionation of heparin using antithrombin III reversibly bound to concanavalin A-SepharoseAnalytical Biochemistry, 1981
- Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin IIIThrombosis Research, 1977